Eighty-seven organisms were tested against ceftriaxone, cefotaxime, desacetylcefotaxime, and the combination of cefotaxime and desacetylcefotaxime (1:1 ratio) in broth containing 0, 25, or 50% human serum. In the presence of human serum, ceftriaxone MICs were four-to eightfold higher than those obtained in broth, changing 98% of Staphylococcus aureus strains from the susceptible to the moderately susceptible category and 53% of selected gram-negative strains to a more resistant category. The MICs of cefotaxime, desacetylcefotaxime, and cefotaxime plus desacetylcefotaxime were not adversely affected by human serum; in fact, the bactericidal activity was slightly improved.
Serum protein binding by antimicrobial agents can profoundly affect pharmacokinetic properties and antimicrobial activity (4, 5, 8, 16, 18, 19) . In an earlier report (2) , we demonstrated that the antistaphylococcal activities of two cephalosporins (cefonicid and ceforanide) tested with human serum were very different, although tests by standardized broth methods generally showed similar spectra. These results favoring ceforanide were attributed to the 98% protein binding of cefonicid.
Other newer cephalosporins, i.e., cefotaxime and ceftriaxone, with very similar antimicrobial spectra (7, 13) also greatly differ in their serum half-lives, tissue distribution, and protein binding. In addition, cefotaxime can be metabolized to desacetylcefotaxime, an active compound most similar in activity to some older cephems, such as cefuroxime (3) . Favorable synergistic and additive interactions have been reported in vitro and in vivo and attributed to the presence of the desacetyl metabolite (3, 17) . Ceftriaxone is not significantly metabolized, but it does have >95% protein binding compared with 10 to 40% for cefotaxime or desacetylcefotaxime (13, 15) .
The purpose of this investigation was to determine the influence of human serum proteins on the in vitro antimicrobial activity of ceftriaxone, cefotaxime, desacetylcefotaxime, and cefotaxime plus desacetylcefotaxime. Broth microdilution susceptibility tests were performed with 51 oxacillin-susceptible Staphylococcus aureus (26 penicillinase producers) strains, 2 enterococci, and 6 Acinetobacter spp., 3 Pseudomonas aeruginosa, 1 Pseudomonas cepacia, 1 Pseudomonas fluorescens, 1 Pseudomonas maltophilia, 4 Enterobacter aerogenes, 4 Enterobacter cloacae, 2 Klebsiella oxytoca, 2 Morganella morganii, 1 Providencia stuartii, and 9 Serratia marcescens strains. Serial twofold dilutions of each drug and the combination of cefotaximedesacetylcefotaxime (1:1 ratio) were tested in cationsupplemented Mueller-Hinton broth in concentrations ranging from 0.5 to 32 ,ug/ml. The broth was also diluted with 25 and 50% (vol/vol) of a heat-inactivated human serum pool taken from two normal healthy volunteers. Growth control experiments using Mueller-Hinton broth with and without 50% serum were conducted with each isolate. Strains that * Corresponding author.
were inhibited by the serum are not included in this report: nine isolates showed reduced serum growth rates. The tests were performed by procedures outlined by the National Committee for Clinical Laboratory Standards (11) and published by Barry et al. (2) .
The bactericidal activity of all drugs and the combination were determined for the 51 staphylococci. Duplicate 10-,ul samples were removed from each well without growth after 24 h at 35°C. The initial inocula were determined and ranged from 3 x 105 to 1 x 106 CFU/ml. The MBC was defined as the lowest concentration producing .99.9% killing of the original inoculum, using the appropriate rejection values of Pearson et al. (12) . Several strains demonstrated a paradoxical effect when the drugs were tested in broth alone; i.e., heavy growth was often observed when wells containing .16 jig/ml were subcultured, although lower concentrations were clearly bactericidal. The effect was generally eliminated by the addition of serum. Gram-negative bacteria were not examined for bactericidal activity. These isolates were selected from a larger stock culture collection in the presence of elevated cefotaxime or ceftriaxone MICs (0.5 to 32 ,ug/ml). For only eight strains were MICs greater than two doubling dilutions above or below the susceptible breakpoint (c8 ,ug/ml) for each cephalosporin tested (11).
The results of testing 51 S. aureus strains in broth and in broth with 25 or 50% human serum are shown in Table 1 . A marked effect of serum on the ceftriaxone MICs and MBCs was demonstrated. The ceftriaxone MIC for 50o of isolates tested (MIC50) increased one log2 dilution when 25% serum was added, and another twofold increase was observed with a 50% serum concentration. This produced a susceptibility category shift from susceptible (c8 ILg/ml) to moderately susceptible (16 or 32 jig/ml) for all but one of the tested staphylococci. Six strains were not killed (MBC, >32 ,ug/ml) by ceftriaxone in broth, but in the presence of 50o serum, there was only one strain for which the MBC was >32 ,ug/ml. Cefotaxime, cefotaxime-desacetylcefotaxime, and desacetylcefotaxime (data not shown) MICs were not significantly affected by the addition of serum to the in vitro test system. Generally, the combination of cefotaxime-desacetylcefotaxime showed minimal variation. The desacetylcefotaxime MIC and MBC for 90% of isolates tested (MIC"0 and MBC90) in 50% serum were equal to those of cetriaxone, i.e., 32 ,ug/ml. All S. aureus isolates remained susceptible to cefotaxime or cefotaxime-desacetylcefotaxime by serumsupplemented MIC determinations, and 92 to 94% were susceptible by bactericidal test results.
The results of similar tests with 34 gram-negative organisms selected for elevated broth MICs of ceftriaxone or cefotaxime are shown in Table 2 . Two-and fourfold increases in ceftriaxone MIC occurred when 25 and 50% human serum were added to the test broth, respectively. In contrast, cefotaxime MICs remained essentially unchanged. However, the combination of cefotaxime-desacetylcefotaxime showed a slight skewing toward lower MICs with serum supplementation (0.8-log2 decrease in MICs with 50% serum added).
Among these selected gram-negative bacilli, elevated ceftriaxone MICs resulted in 12 (35%) organisms becoming more resistant (moderately susceptible or resistant category) when tested in 25% serum, and 18 (53%) strains were more resistant in 50% serum. Essentially equal numbers (two to five strains) of gram-negative bacilli became more resistant or more susceptible to cefotaxime and cefotaxime tested with its metabolite in serum.
Two enterococci were also tested. An Enterococcus faecium strain demonstrated the ability of serum to enhance the antimicrobial activity of these amino-thiazolyloximino cephalosporins (14) . Fifty-percent serum was required for an E. faecalis strain to show susceptible-range MICs of cefotaxime and the cefotaxime-desacetylcefotaxime combination, whereas no change was observed for ceftriaxone.
These studies extend our earlier report on the effects of human serum on the antimicrobial activity of newer highly protein-bound cephalosporins (2) . In this study, the antimicrobial activity of ceftriaxone against S. aureus and some isolates of gram-negative bacilli was markedly compromised, resulting in susceptibility category (11) changes for nearly all staphylococci and 53% of selected gram-negative strains. In contrast, cefotaxirne was not adversely influenced by serum, and its association with an active metabolite, desacetylcefotaxime, showed a tendency toward greater activity and an MBC closer to the MIC. Several reports have documented the advantageous features of antimicrobial agents that have active metabolites (3) .
Ceftriaxone is predominantly bound to serum albumin. Because of its protein binding (>95%), serum supplementation in in vitro tests alters the results in a manner comparable to that reported for the isoxazolyl penicillins (4, 8, 18, 19) , fusidic acid (4), and cefonicid (2) . Ceftriaxone has nonlinear dose pharmacokinetics directly related to concentrationdependent serum protein binding. Its limited volume of distribution expands with higher dosing, but the free unbound ceftriaxone distribution does not increase (13, 15) .
The controversial issues regarding the effects of protein binding on the clinical efficacy of a drug and methods for in vitro testing have been the subject of numerous reviews and studies since the mid-1940s (5, 8, 16, 18, 19) . Generally, 4-to 16-fold increases in MICs for organisms can be expected in the presence of serum for antimicrobial agents having .95% protein binding (4, 5, 8, 18, 19) . Binding to proteins of 0 to 90% reduces the concentration of free drug in serum and tissues by no more than half (5). Furthermore, susceptible interpretive breakpoints for the older penicillinase-resistant penicillins are more closely related to free drug after parenteral or oral administration (11). Confirming information recently obtained from animal models demonstrated a direct relationship between free drug and cephalosporin therapeutic efficacy (1).
In the presence of 50% serum, the ceftriaxone MIC90 for S. aureus was 32 jig/ml, and that concentration of circulating drug can be expected 10 h after a 1-g dose (42% of the 24-h dose interval). The gram-negative coverage of ceftriaxone would also be reduced for the selected members of the family Enterobacteriaceae for which aminothiozolylmethoxyimino cephalosporin MICs range from 2 to 32 ;,jg/ml. These selected strains represent approximately 5% of all enteric bacilli (6) . Cefotaxime activity, being unaffected by serum proteins, would have levels in serum (1 g intravenously) greater than the staphylococcal MIC9o for more than half the commonly used 8-h dosing interval (10) . More gram-negative isolates among the enteric bacilli, acinetobacters, and some Pseudomonas species would be susceptible to cefotaxime tested in serum than to ceftriaxone. This fact TABLE 2. Effect of adding human serum to broth in vitro susceptibility tests with 22 members of the Enterobacteriaceae, 6 Acinetobacter spp., and 6 Pseudomonas spp. seriously challenges the spectrum-class concept of the National Committee for Clinical Laboratory Standards that states that cefotaxime and ceftriaxone have similar antimicrobial coverages (11) and raises the question as to the most appropriate test medium for susceptibility assays of highly protein-bound antimicrobial agents. Additional clinical outcome data correlated with these in vitro studies is required to resolve these questions.
Although serum proteins may adversely influence some newer cephalosporins, increased activity of cephems with a methoxyimino group against many enterococci has been reported (14) . Also, these same cephalosporins may potentiate bactericidal activity of human neutrophils against S. aureus strains (9) . Thus, the factors influencing the choices of newer cephalosporins for chemotherapy remain complex, especially in the area of effective dosing intervals and the role of serum protein binding.
